Xolair 150 MG/ML autoinjectorml
Ended Awarded Last action
- Contract number
- SPE2DR26FCZE4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $13,106
Award facts
- Contract value 100% obligated
- $13,105.80 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $13,105.80 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 150 mg/mL autoinjector. The delivery order, issued on January 7, 2026, with an ultimate completion date of January 29, 2026, carries no set-aside designation, indicating the award was made through unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a comprehensive $30.3 billion acquisition strategy designed to streamline pharmaceutical procurement for Department of Defense healthcare operations.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal military pharmaceutical supply chain since its initial SAM registration in 2001. The company's IDC, designated contract SPE2DR and valued at $499,999,999 through December 31, 2036, positions it as a regional prime vendor capable of supplying a diverse portfolio of pharmaceuticals including branded and generic medications, biologics, vaccines, and specialty products to support DoD medical facilities worldwide. Xolair, an immunosuppressant biologic agent, exemplifies the specialized pharmaceutical products the contractor regularly delivers under this contract vehicle, fulfilling recurring medical supply requirements across the military healthcare system.
Quick answers
Who was awarded contract SPE2DR26FCZE4?
SPE2DR26FCZE4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 7, 2026.
How much is contract SPE2DR26FCZE4 worth?
The government has obligated $13,106 on SPE2DR26FCZE4.
Is contract SPE2DR26FCZE4 an order under another contract?
Yes. SPE2DR26FCZE4 is a delivery order under SPE2DR25D9127, an indefinite delivery contract.
Was contract SPE2DR26FCZE4 competed?
The extent of competition for SPE2DR26FCZE4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award